Graft Versus Leukemia: Current Status and Future Perspectives

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01801 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434054 Graft Versus Leukemia: Current Status and Future Perspectives Aideen T. O'Neill, MBBS, MRCP, FRCPath1xAideen T. O'NeillSearch for articles by this author and Ronjon Chakraverty, MBChB, MRCP, FRCPath, PhD1xRonjon ChakravertySearch for articles by this author Show More 1MRC Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom https://doi.org/10.1200/JCO.20.01801 First Page Full Text PDF Figures and Tables Supplements © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveRelapse of hematologic malignancy is the major reason for treatment failure after allogeneic stem cell transplantation.Knowledge GeneratedGraft-versus-leukemia (GVL) responses are critical to prevent relapse but may fail as a result of tumor immune evasion, for example through antigen loss or T cell dysfunction. In silico pipelines for the discovery of tumor-expressed antigens and novel therapies that target immune evasion mechanisms (small molecule, biological, immune cell transfer) are potential strategies to sustain or reimpose GVL.RelevanceA key challenge will be how experimental therapies to enhance GVL can progress from first-in-human trials to prospective, controlled trials that evaluate efficacy and lead to regulatory approval.